NASDAQ:MBVXMabvax Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mabvax Therapeutics Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.02 0.00 (0.00 %) (As of 03/19/2020) Add Compare Share Today's Range$0.02Now: $0.02▼$0.0250-Day Range$0.01MA: $0.38▼$1.1552-Week Range$0.10Now: $0.02▼$2.55Volume1,333 shsAverage Volume31,620 shsMarket Capitalization$212,865.00P/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company's product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company's HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Mabvax Therapeutics. Previous Next 2.1 Community Rank Outperform VotesMabvax Therapeutics has received 217 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMabvax Therapeutics has received 296 “underperform” votes. (Add your “underperform” vote.)Community SentimentMabvax Therapeutics has received 57.70% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mabvax Therapeutics and other stocks. Vote “Outperform” if you believe MBVX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MBVX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMabvax Therapeutics does not currently pay a dividend.Dividend GrowthMabvax Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mabvax Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 14.76% of the stock of Mabvax Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.72% of the stock of Mabvax Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.42 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MBVX Previous SymbolOTCMKTS:TELKD CUSIPN/A CIK1109196 Webwww.mabvax.com Phone858-259-9405Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares9,255,000Market Cap$212,865.00 Next Earnings DateN/A OptionableNot Optionable Receive MBVX News and Ratings via Email Sign-up to receive the latest news and ratings for MBVX and its competitors with MarketBeat's FREE daily newsletter. Mabvax Therapeutics (NASDAQ:MBVX) Frequently Asked Questions How were Mabvax Therapeutics' earnings last quarter? Mabvax Therapeutics Holdings Inc (NASDAQ:MBVX) announced its quarterly earnings results on Tuesday, November, 7th. The company reported ($1.62) EPS for the quarter. View Mabvax Therapeutics' earnings history. When did Mabvax Therapeutics' stock split? How did Mabvax Therapeutics' stock split work? Mabvax Therapeutics shares reverse split on the morning of Friday, February 16th 2018. The 1-3 reverse split was announced on Thursday, February 15th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 15th 2018. An investor that had 100 shares of Mabvax Therapeutics stock prior to the reverse split would have 33 shares after the split. Has Mabvax Therapeutics been receiving favorable news coverage? News coverage about MBVX stock has been trending somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mabvax Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term. View the latest news aboutMabvax Therapeutics. Who are some of Mabvax Therapeutics' key competitors? Some companies that are related to Mabvax Therapeutics include Argos Therapeutics (ARGSQ), Sienna Biopharmaceuticals (SNNAQ), Achaogen (AKAOQ), HST Global (HSTC), ProMetic Life Sciences (PFSCF), Spotlight Innovation (STLT), Skinvisible (SKVI), Sophiris Bio (SPHS), Respirerx Pharmaceuticals (RSPI), Targeted Medical Pharma (TRGM), Orexigen Therapeutics (OREXQ), Propanc Biopharma (PPCB), Inspyr Therapeutics (NSPX), Immune Therapeutics (IMUN) and Advanz Pharma (CXRXF). View all competitors. What other stocks do shareholders of Mabvax Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mabvax Therapeutics investors own include Immunomedics (IMMU), GW Pharmaceuticals PLC- (GWPH), Athersys (ATHX), Dollar General (DG), Gilead Sciences (GILD), Zynerba Pharmaceuticals (ZYNE), Depomed (DEPO), Celgene (CELG), Galectin Therapeutics (GALT) and Protalix Biotherapeutics (PLX). Who are Mabvax Therapeutics' key executives? Mabvax Therapeutics' management team includes the following people: Mr. John David Hansen, Chairman, Pres & CEO (Age 67)Prof. Philip O. Livingston, Co-Founder, Chief Science Officer & Director (Age 75)Mr. Gregory P. Hanson C.M.A., M.B.A., MBA, CMA, Chief Financial Officer (Age 71)Dr. Paul W. Maffuid, Exec. VP of R&D (Age 63)Dr. Paul F. Resnick, VP & Chief Bus. Officer (Age 61) What is Mabvax Therapeutics' stock symbol? Mabvax Therapeutics trades on the NASDAQ under the ticker symbol "MBVX." What is Mabvax Therapeutics' stock price today? One share of MBVX stock can currently be purchased for approximately $0.02. How big of a company is Mabvax Therapeutics? Mabvax Therapeutics has a market capitalization of $212,865.00. What is Mabvax Therapeutics' official website? The official website for Mabvax Therapeutics is www.mabvax.com. How can I contact Mabvax Therapeutics? Mabvax Therapeutics' mailing address is 11535 SORRENTO VALLEY ROAD SUITE 400, SAN DIEGO CA, 92121. The company can be reached via phone at 858-259-9405 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
